Modern concept of prevention of tumor breast pathology


  • Ю. П. Вдовиченко P.L. Shupik National Medical Academy of the Postgraduate Education, Ukraine
  • В. А. Потапов SE “Dnipropetrovsk medical academy of Health Ministry of Ukraine”, Ukraine



fibrocystic breast disease, therapy, prevention of breast cancer, Epigalin Brest


In the article the data on the genetic and molecular and epigenetic mechanisms of carcinogenesis, shows the evolution of phenotypic similarity benign hyperplastic processes of mammary glands and breast cancer (BC). With critical positions represented a modern strategy for the prevention and treatment of breast cancer, benign breast disease, conducted an analysis of a number of pharmacological efficacy of drugs for these purposes are disclosed benefits of targeted therapy with phytonutrients.

From the standpoint of evidence-based discussion about onkoprotection properties mediating most of the major pathogenetic links hyperproliferation and tumor growth in mammary glands, fitocomposition Epigalin Brest, active ingredients which are natural dopamine agonist – Vitex agnus-castus extract usual and the two most famous fitoprotection targeted 3,3-Diindolymethane and epigallocatechin-3-gallate, as well as the possibility of using Epigalin Brest as multitargeted therapy benign breast disease and prevention of carcinogenesis in women at risk for breast cancer.

It is concluded that Epigalin Brest is unique fitoresources as an additional component to the diet daily diet in order to maintain the normal state of function of cells and natural deterministic genetic mechanisms onkoprotection as in patients with benign breast disease, and in healthy women who want to make informed choices in relation to the safe the prevention of breast cancer, the risk of developing that over the life of each woman has.

Author Biographies

Ю. П. Вдовиченко, P.L. Shupik National Medical Academy of the Postgraduate Education

MD, corresponding member of the NAMS of Ukraine, professor at the Obstetrics, Gynecology and Perinatology Department

В. А. Потапов, SE “Dnipropetrovsk medical academy of Health Ministry of Ukraine”

MD, professor, head of Obstetrics and Gynecology Department


  1. Ashrafyan, L.A., Kiselev, V.I., Muizhnek, E.L. Pathogenetic prophylaxis of reproductive organs cancer. Moscow. Dimitreid Graphic Group (2009): 176 p.
  2. Baranov, V.S. Genetic passport – the basis of individual and preliminative medicine. St. Petersburg. Publishing House N-L (2009): 528 p.
  3. Burdina, L.M. “Dyshormonal hyperplasia of mammary glands – features of development and differential diagnostics.” Radiol Pract 3 (2007): 44–61.
  4. Veropotvelyan, P.N., Veropotvelyan, N.P., Suhina, T.V. “Diseases of the mammary glands associated with hereditary pathology.” Women’s health 5.41 (2009): 204–12.
  5. Vysotskaya, I.V. “Modern possibilities of therapy of fibrocystic disease.” Tumors of the female reproductive system 1–2 (2009): 44–6.
  6. Galitsky, V.A. “Carcinogenesis and mechanisms of intracellular signaling.” Questions of oncology 49.3 (2003): 278–93.
  7. Goryushina, O.G. “The role of prolactin in the genesis of mastopathy.” Herald of new medical technologies 4 (2002): 22–4.
  8. Goryacheva, L.A., Pinhosevich, E.G. Phytotherapy for breast diseases. Moscow (2006): 23 p.
  9. Gromova, O.A., Rebrov, V.G. “Vitamins and carcinogenesis: myths and reality.” Reproductive health of children and adolescents 1 (2005): 80–96.
  10. Dedov, I.I., Melnichenko, G.A., Romantsova, T.I. Syndrome of hyperprolactinemia. Moscow (2004): 304 p.
  11. Zotov, A.S., Belik, E.O. Mastopathy and breast cancer. Moscow. MEDpress-inform (2005): 112 с.
  12. Zulkarnaeva, E.T., Hakimova, R.H., Lapan, E.I., Blagodetev, I.L. “Indinol-3-carbinol in the treatment of benign breast diseases.” Tumors of the female reproductive system 3 (2008): 50–4.
  13. Kiselev, V.I., Lyashenko, A.A. Indinol – the regulator of proliferative processes in the organs of the reproductive system. Moscow. ZAO MiraxPharma (2008): 48 p.
  14. Kiselev, V.I., Lyashenko, A.A. Molecular mechanisms of regulation of hyperplastic processes. Moscow: Dimitreid Graphic Group (2005): 348 p.
  15. Kuligina, E.Sh. “Epidemiological and molecular aspects of breast cancer. ” Pract oncology 11.4 (2010): 203–16.
  16. Letyagin, V.P., Vysotskaya, I.V. “Treatment of diffuse fibrocystic disease.” Tumors of the female reproductive system 2 (2007): 47–9.
  17. Mustafin, Ch.K., Kuznetsova, S.V. Dyshormonal diseases of the mammary gland / Ed. by E.G. Pinhosevich. Moscow (2009): 126 p.
  18. Nosov, D.A. “Target therapy of malignant neoplasms.” Together against cancer. Special issue (2004): 17–24.
  19. Ovsyannikova, Т.V. “Dyshormonal pathology of mammary glands – gynecologist’s view.” Benign breast disease 10 (2006): 22–38.
  20. Osinskyi, S.P., Gluzman, D.F., Cliff, J., et al. Molecular diagnostics of tumors. Kyiv. DIA (2007): 246 p.
  21. Pak, D.D., Usov, F.N., Fetisova, E.Y., et al. “Modern approaches to the treatment of patients with carcinoma in situ of the breast.” Oncology 4 (2013): 34–9.
  22. Popov, B.V. Introduction to stem biology of stem cells. St. Petersburg (2010): 319 p.
  23. Potapov, V.A. “The role of epigenetic factors in tumor pathology of the uterus and breast.” With care for woman 7.55 (2014).
  24. Prilepskaya, V.N., Tagieva, T.T. “Fibrous-cystic disease of mammary glands: the possibility of non-hormonal therapy.” Medline-Express 5 (2008): 10–17.
  25. Order of the MOH of Ukraine No. 676 from 31.12.2004. Prophylaxis and diagnosis of dyshormonal diseases of the breast: a clinical protocol.
  26. Radzinskyi, V.E. Mammary glands and gynecological diseases. Moscow (2010): 304 p.
  27. Radzinskyi, V.E., Ordiyants, I.M. “Premenstrual syndrome and benign breast dysplasia: realities and perspectives.” Women’s health 1.57 (2011): 71–5.
  28. Order of the MOH of Ukraine No. 396 from 30.06.2015. Breast cancer: a unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care.
  29. Sergeeva, N.I., Dzeranova, L.K., Meskikh, E.V., et al. “Participation of prolactin in mammogenesis and carcinogenesis of the breast.” Obstetrics and gynecology 3 (2005): 13–17.
  30. Tagieva, Т.Т. “Mastopathy: non-hormonal methods of treatment. ” Gynecology 6.5 (2004): 228–30.
  31. Tarutinov, V.I. Breast: cancer and precancerous diseases. Kyiv. Kniga Plus (2009): 479 p.
  32. Tovstanovskaya, V.A., Vorobei-Vikhovskaya, V.N., Sakharova, I.A. “A new word in non-hormonal therapy of fibrocystic mastopathy.” Women’s health 1.47 (2010): 64–6.
  33. Phillipov, O.S. Benign breast diseases. Moscow. MEDpress (2008): 112 p.
  34. Chaika, V.K., Sergienko, M.Y., Zheltonozhenko, L.V. “Treatment of patients with dyshormonal diseases of mammary glands from the position of endocrinological gynecology.” Russian bulletin of the obstetrician-gynecologist 1 (2009): 71–5.
  35. Chesnokova, N.P., Barsukov, V.Y., Zlobnova, O.A. “Breast cancer: pathogenesis problems.” Fundamental researches 4–1 (2012): 146–51.
  36. Yalkut, S.I., Potebnya, G.P. Biotherapy of tumors. Kyiv. Kniga Plus (2010): 472 p.
  37. Auborn, K.J., Fan, S., Rosen, E.M., et al. “lndole-3-carbinol is a negative regulator of estrogen. ” J Nutr 133 Suppl 7 (2003): 2470–5.
  38. Bradlow, H.I., Telang, N.T., Sepkovic, D.W., et al. “2-hydroxyestrone, the ‘good’ estrogen.” J Endocrinol 150 (1996): 259–65.
  39. Brandi, G., Paiardini, M., Cervasi, B., et al. “A new indole-3-carbinol tetrameric derivative inhibits cyclindependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.” Cancer Res 63.14 (2003): 4028–36.
  40. Brignall, M.S. “Prevention and treatment of cancer with indole-3-carbinol.” Altern Med Rev 6 (2001): 580–9.
  41. Castillo, E., Garibay, M., Mirabent, F. “Effect of alfa dihydroergocriptine in patients with fibrocistiс breast disease.” Gynecol Obstet Mex 74 (2006): 580–4.
  42. Chen, P., Yang, C.C., Chen, Y.J., Wang, P.H. “Tamoxifen-induced endometrial cancer.” Eur J Gynaecol Oncol 24.2 (2003): 135–7.
  43. Cover, С.М., Hsieh, S.J., Cram, E.J. “lndole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells.” Cancer Res 59.6 (1999): 1244–51.
  44. Daniele, C., Thompson Coon, J., Pittler, M.H., Ernst, E. “Vitex agnus castus: a systematic review of adverse events.” Drug Saf 28 (2005): 319–32.
  45. Gardner, D.G., Shoback, D. Basic and clinical endocrinology. Moscow. Binom-Press (2010): 464 p.
  46. Fuller, G.M., Shields, D. Molecular cell biology. Moscow. Binom-Press (2013): 256 p.
  47. Firestone, G.L., Bjeldanes, L.F. “lndole-3-carbinol and З-З’-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions.” J Nutr 133.7 (2003): 2448–55.
  48. Freedman, A.N., Seminara, D., Gail, M.H., et al. “Cancer risk prediction models: a workshop on development, evaluation, and application.” J Natl Cancer Inst 97 (2005): 715–23.
  49. Guray, M., Sahin, A.A. “Benign breast diseases: classification, diagnosis, and management.” Oncologist 11 (2006): 435–49.
  50. Jung, Y.D., Ellis, L.M. “Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea.” Int J Exp Pathol 82.6 (2001): 309–16.
  51. Kastan, M.B., Bartek, J. “Cell-cycle checkpoints and cancer.” Nature 116 (2004): 273–9.
  52. KiIicdag, Е.В. “Fructus agni casti and bromocriptine for treatinent of hyperprolactinemia and mastalgia.” Intl J Gyn & Ob 85 (2004): 292–3.
  53. Knudson, A.G. “Cancer genetics.” Am J Ved Genet 111 (2002): 96–102.
  54. Kumru, A.M., Tezcan, S.E. “Fluoxetine Versus Vitex agnus castus extrakt in the treatment of premenstrual disorder.” Hum Psychopharmacol 18.3 (2003): 191–5.
  55. Liang, Y.C., Lin-Shiau, S.Y., Chen, C.F., et al. “Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by epigallocatechin-3-gallate.” Lin J Cell Biochem 75 (1999): 1–12.
  56. Lewin, B., Cassimeris, L., Lingappa, V.R., Plopper, G. Cells. Moscow. BINOM. Laboratory of Knowledge (2011): 951 p.
  57. Lewin, B. Genes. Moscow: BINOM. Laboratory of Knowledge (2012): 896 p.
  58. Massague, J. “G1 cell-cycle control and cancer.” Nature 432 (2004): 298–306.
  59. Martin, G.S. “The hunting of the Src.” Nat Rev Mol Cell Biol 2 (2001): 467–75.
  60. Martinez-Arribas, F., Nunez-Villar, M.J., Luca, A.R., et al. “Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.” Anticancer Res 23.1 (2003): 565–8.
  61. Miltenburg, D.M., Speights, V.O. “Benign breast disease.” Obstet Gynecol Clin North Am 35 (2008): 285–300.
  62. Rabson, A., Roitt, I.M., Delves, P.J. Fundamentals of medical immunology. Moscow. Mir (2006): 320 p.
  63. Santen, R.J., Mansel, R. “Benign breast disorders.” N Engl J Med 353 (2005): 275–85.
  64. Sarkar, F.H., Rahman, K.M., Li, Y. “Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol (I3C) treatment of breast cancer cells.” J Nutr 133.7 (2003): 2434–9.
  65. Wuttke, W., Jarry, H., Christoffel, V. “Chaste tree (Vitex agnus-castus) – pharmacology and clinical indications.” Phytomed 10 (2003): 348–57.
  66. Yang, C.S., Landau, J.M., Huang, M.T., Newmark, N.L. “Inhibition of carcinogenesis by dietary polyphenolic compounds.” Annu Rev Nutr 21 (2001): 381–406.



How to Cite

Вдовиченко, Ю. П., & Потапов, В. А. (2017). Modern concept of prevention of tumor breast pathology. REPRODUCTIVE ENDOCRINOLOGY, (35), 17–30.



Tumors and pretumoral pathology